Cure for Relapsed Lymphoma? Long-Term Data on Curocell's Rimqarto CAR-T Therapy Revealed at ASH 2026
AI 요약 정보
- Curocell's Rimqarto data selected for ASH 2026 poster
- Among 73 relapsed/refractory large B-cell patients, ORR is 75.3%
- Rimqarto follow-up median 14.6 months; 3-year OS 53.5%